If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
The Lowry protein assay is a biochemical assay for determining the total level of protein in a solution. The total protein concentration is exhibited by a color change of the sample solution in proportion to protein concentration, which can then be measured using colorimetric techniques. It is named for the biochemist Oliver H. Lowry who developed the reagent in the 1940s. His 1951 paper describing the technique is the most-highly cited paper ever in the scientific literature, cited over 300,000 times.
== History == The effectiveness and safety of apitegromab were evaluated in a 52-week randomized, double-blind, placebo-controlled trial (NCT05156320). The trial enrolled 188 participants with spinal muscular atrophy between 2 to 21 years of age who were not able to move or walk independently. All participants were already receiving an approved survival motor neuron 2-targeted treatment. Participants were randomly assigned to receive apitegromab 10 mg/kg, apitegromab 20 mg/kg via intravenous infusion, or placebo once every four weeks for approximately one year. The primary analysis was conducted in 156 participants aged 2 to 12 years of age.
== Artificial D-amino acid dehydrogenase == Due to the drawbacks of current methods, researchers have begun work on creating an artificial enzyme capable of producing the same D-amino acids as enzymes from naturally occurring sources. By adding five amino acids to a given sample isolated from U. thermosphaericus, they succeeded. By modifying the amino acid sequence, researchers were able to change the specificity of the molecule towards certain reactants and products, showing that it may be possible to use artificial D-amino acid dehydrogenase to screen for certain D-amino acid products.
AOD9604 is an orally active, lipolytic 16-amino acid peptide fragment of human growth hormone and derivative of the C-terminal domain of human growth hormone (HGH). It consists of HGH residues 176–191, with a tyrosine in place of the phenylalanine at the N-terminal end. Initial human trials showed that it retains the lipolytic properties of human growth hormone without stimulating IGF-1 production. However, later studies failed to demonstrate a sufficient lipolytic effect. Its development was terminated in 2007. Despite its limited efficacy, AOD9604 is still banned in athletes and tested for in competition.
genomic island (GI) A region of a genome that shows evidence of horizontal transfer from another organism. The term is used especially in describing microbial genomes such as those of bacteria, where genomic islands having the same or similar sequences commonly occur in species or strains that are otherwise only distantly related, implying that they were not passed on through vertical descent from a common ancestor but through some form of lateral transfer such as conjugation. These islands often contain functional genes which confer adaptive traits such as antibiotic resistance.
Sources: en.wikipedia.org
Secondary structure prediction is a set of techniques in bioinformatics that aim to predict the local secondary structures of proteins based only on knowledge of their amino acid sequence. For proteins, a prediction consists of assigning regions of the amino acid sequence as likely alpha helices, beta strands (often termed extended conformations), or turns. The success of a prediction is determined by comparing it to the results of the DSSP algorithm (or similar e.g. STRIDE) applied to the crystal structure of the protein. Specialized algorithms have been developed for the detection of specific well-defined patterns such as transmembrane helices and coiled coils in proteins. The best modern methods of secondary structure prediction in proteins were claimed to reach 80% accuracy after using machine learning and sequence alignments; this high accuracy allows the use of the predictions as feature improving fold recognition and ab initio protein structure prediction, classification of structural motifs, and refinement of sequence alignments. The accuracy of current protein secondary structure prediction methods is assessed in weekly benchmarks such as LiveBench and EVA.
{\displaystyle {\begin{aligned}F_{1}(kr)&={\frac {\mathrm {ber} (kr)\mathrm {ber} (kR)+\mathrm {bei} (kr)\mathrm {bei} (kR)}{\mathrm {ber} ^{2}(kR)+\mathrm {bei} ^{2}(kR)}},\\[6pt]F_{2}(kr)&={\frac {\mathrm {ber} (kr)\mathrm {bei} (kR)-\mathrm {bei} (kr)\mathrm {ber} (kR)}{\mathrm {ber} ^{2}(kR)+\mathrm {bei} ^{2}(kR)}},\end{aligned}}}
Subsequently, ADP-actin dissociates slowly from the pointed end, a process significantly accelerated by the actin-binding protein, cofilin. ADP bound cofilin severs ADP-rich regions nearest the (−)-ends. Upon release, the free actin monomer slowly dissociates from ADP, which in turn rapidly binds to the free ATP diffusing in the cytosol, thereby forming the ATP-actin monomeric units needed for further barbed-end filament elongation. This rapid turnover is important for the cell's movement. End-capping proteins such as CapZ prevent the addition or loss of monomers at the filament end where actin turnover is unfavorable, such as in the muscle apparatus. Actin polymerization together with capping proteins were recently used to control the 3-dimensional growth of protein filament so as to perform 3D topologies useful in technology and the making of electrical interconnect. Electrical conductivity is obtained by metallisation of the protein 3D structure.
La Familia Michoacana was a drug cartel based in Michoacán between at least 2006 and 2011. It was formerly allied with the Gulf Cartel and Los Zetas, but split off to become an independent organization. La Familia Michoacana was the first cartel targeted by President Calderón's security strategy, beginning with Operation Michoacán in December 2006. Between 2009 and 2010, joint U.S.–Mexican operations led to the arrest of hundreds of La Familia members and the reported death of founder Nazario Moreno González ("El Más Loco"). The group soon split between the Knights Templar Cartel and a faction led by José de Jesús Méndez Vargas ("El Chango"), who was arrested in 2011, after which authorities declared La Familia dismantled, leaving the Knights Templar as its de facto successor. In February 2010, La Familia allied with the Gulf Cartel against Los Zetas and the Beltrán-Leyva Cartel. La Nueva Familia Michoacana emerged from splinters of La Familia in the early 2010s, rebranding while continuing operations in Michoacán and Guerrero, and clashing with the Jalisco New Generation Cartel.
== Research and teaching == Strobel's research focuses on the biophysics and biochemistry of catalytic RNAs, including riboswitches and peptidyl transferase. His group developed the early methods of Nucleotide Analog Interference Mapping, used to determine the importance of particular functional groups in a structured RNA molecule. Strobel's group solved the x-ray crystal structure of the full length Azoarcus Group I catalytic intron, the glmS ribozyme, and the c-di-GMP riboswitch. He has also collaborated with the Thomas A. Steitz lab at Yale on structural studies toward better understanding the mechanism of ribosomal peptide synthesis. He was twice named a HHMI professor to promote undergraduate science education. With this award he instituted an undergraduate research course, the Rainforest Expedition and Laboratory, which explored microbial and chemical diversity in the world's rainforests as a means to inspire undergraduate students in the sciences. He has led groups of undergraduate students into the rainforest over spring break to hunt for novel endophytes that live inside plants. Following fieldwork, students then isolated microbes and tested them for interesting properties, discovering a variety of organisms including novel fungi with new biological and chemical properties, including Pestalotiopsis microspora, of which some strains degrade polyurethane.
Sources: en.wikipedia.org
== Further reading == Kelly, Evelyn B. (2013-01-07). Encyclopedia of Human Genetics and Disease [2 volumes]. ABC-CLIO. ISBN 9780313387142. Carakushansky, Gerson; Ribeiro, Marcia Gonçalves; Kahn, Evelyn (2011). "Moderately progressive Ullrich congenital muscular dystrophy". Jornal de Pediatria. 88 (1): 93–96. doi:10.2223/JPED.2112. ISSN 0021-7557. PMID 22016142. "National Guideline Clearinghouse | Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular and Electrodiagnostic Medicine". www.guideline.gov. Archived from the original on 2016-04-08. Retrieved 2016-05-12. Hicks, D.; Lampe, A. K.; Laval, S. H.; Allamand, V.; Jimenez-Mallebrera, C.; Walter, M. C.; Muntoni, F.; Quijano-Roy, S.; Richard, P.; Straub, V.; Lochmuller, H.; Bushby, K. M. D. (16 November 2008). "Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue" (PDF). Brain. 132 (1): 147–155. doi:10.1093/brain/awn289. PMID 19015158. Retrieved 12 May 2016.
Load-induced non-rupture tendinopathy in humans is associated with an increase in the ratio of collagen III:I proteins, a shift from large to small diameter collagen fibrils, buckling of the collagen fascicles in the tendon extracellular matrix, and buckling of the tenocyte cells and their nuclei.
=== Expression across the lifespan === FcRn is highly expressed during the neonatal period, particularly in epithelial and endothelial cells, to support passive immunity through maternal IgG transfer and protection from protein degradation. In adulthood, FcRn expression persists in various tissues including the endothelium, intestinal epithelium, kidney podocytes, and antigen-presenting cells, where it continues to regulate IgG and albumin homeostasis. While overall FcRn function remains critical throughout life, some studies suggest that FcRn expression or activity may decline with aging, potentially contributing to altered antibody pharmacokinetics and immune responses in the elderly.
=== Relapsing-remitting MS === Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis and in reducing the accumulation of brain lesions, which is measured using gadolinium-enhanced magnetic resonance imaging (MRI). Interferons reduce relapses by approximately 30% and their safe profile make them the first-line treatments. Nevertheless, not all the patients are responsive to these therapies. It is known that 30% of MS patients are non-responsive to Beta interferon. They can be classified in genetic, pharmacological and pathogenetic non-responders. One of the factors related to non-respondance is the presence of high levels of interferon beta neutralizing antibodies. Interferon therapy, and specially interferon beta 1b, induces the production of neutralizing antibodies, usually in the second 6 months of treatment, in 5 to 30% of treated patients. Moreover, a subset of RRMS patients with specially active MS, sometimes called "rapidly worsening MS" are normally non-responders to interferon beta 1a. While more studies of the long-term effects of the drugs are needed, existing data on the effects of interferons indicate that early-initiated long-term therapy is safe and it is related to better outcomes.
=== Pre-1970 jury trials === Before they were abolished in 1970, jury trials were conducted to hear capital cases in Singapore since the British colonial era. Based on the verdict of a jury, if a person was found guilty, the judge would convict and impose a penalty to the defendant in accordance to the charge he or she was found guilty of. One notable case in which a person was sentenced to death in a jury trial was the trial of Sunny Ang Soo Suan, who allegedly murdered his girlfriend Jenny Cheok Cheng Kid during a scuba diving trip in 1963. Despite the circumstantial evidence and the absence of the victim's body, the seven-men jury unanimously found Ang guilty of murder and sentenced him to death. Ang was eventually hanged on 6 February 1967 after he lost all his appeals to both the Court of Appeal and the Privy Council, and the failure of his clemency plea to President Yusof Ishak. The first person to be tried before two judges in the High Court and sentenced to death for a capital case was armed robber Teo Cheng Leong, who was found guilty and sentenced in February 1970 for unlawfully discharging a firearm twice when he fired two missed shots at a police officer. Another notable case was the kidnapping and murder of Ong Beang Leck, the son of a rich tycoon. Five men were involved in the abduction and they had murdered Ong after luring him into a rented car on 24 May 1968. Three of the kidnappers were found guilty of murder and sentenced to death in June 1970.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.